Of the two tumor-specific T lymphocyte subsets, CD8+ T cells recognize tumor antigen-derived peptides in the context of MHC class I molecules whereas CD4+ T cells respond to peptide-MHC class II complexes. This evidence concerns the gene CD4 and neoplasm.